Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNASDAQ:RXSTNASDAQ:SIBNNYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.55+1.9%$6.90$5.28▼$14.38$538.04M0.86452,408 shs690,124 shsRXSTRxSight$13.61-1.9%$14.75$12.53▼$60.81$553.07M1.29708,226 shs653,062 shsSIBNSiBone$16.39-1.7%$16.94$11.70▼$20.05$698.46M0.94388,707 shs406,230 shsSTXSStereotaxis$2.04-9.7%$2.08$1.54▼$2.72$175.44M1.46360,677 shs679,866 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%-1.06%+0.61%-32.12%+12.54%RXSTRxSight0.00%-4.22%-14.35%-45.21%-76.15%SIBNSiBone0.00%-5.91%-11.02%+11.80%+32.28%STXSStereotaxis0.00%-3.32%+0.99%+6.25%+10.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus2.583 of 5 stars3.30.00.00.00.04.21.3RXSTRxSight3.021 of 5 stars4.22.00.00.02.81.70.6SIBNSiBone3.5286 of 5 stars3.52.00.03.30.02.50.6STXSStereotaxis0.2872 of 5 stars0.02.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.67Moderate Buy$14.33118.83% UpsideRXSTRxSight 2.30Hold$37.90178.47% UpsideSIBNSiBone 3.00Buy$22.5037.28% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STXS, BVS, RXST, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.005/6/2025SIBNSiBoneTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSiBoneNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.95$0.52 per share12.58$2.80 per share2.34RXSTRxSight$139.93M3.95N/AN/A$6.98 per share1.95SIBNSiBone$167.18M4.18N/AN/A$3.98 per share4.12STXSStereotaxis$26.92M6.52N/AN/A$0.07 per share29.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.24N/A-7.11%15.61%4.01%N/ARXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/4/2025 (Estimated)SIBNSiBone-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)STXSStereotaxis-$24.05M-$0.28N/AN/AN/A-92.19%-325.86%-56.55%8/11/2025 (Estimated)Latest STXS, BVS, RXST, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/5/2025Q1 2025SIBNSiBone-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99RXSTRxSightN/A12.6811.65SIBNSiBone0.218.537.26STXSStereotaxisN/A1.070.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%RXSTRxSight78.78%SIBNSiBone98.11%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%RXSTRxSight9.57%SIBNSiBone4.00%STXSStereotaxis17.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableRXSTRxSight22040.64 million36.75 millionOptionableSIBNSiBone35042.62 million40.91 millionOptionableSTXSStereotaxis13086.00 million70.72 millionNot OptionableSTXS, BVS, RXST, and SIBN HeadlinesRecent News About These CompaniesStereotaxis shareholders approve board nominees and auditorMay 21, 2025 | investing.comEarnings call transcript: Stereotaxis Q1 2025 reports stable EPS, revenue growthMay 14, 2025 | uk.investing.comStereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comStereotaxis, Inc.: Stereotaxis Reports 2025 First Quarter Financial ResultsMay 14, 2025 | finanznachrichten.deStereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...May 14, 2025 | finance.yahoo.comStereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption rampMay 13, 2025 | msn.comStereotaxis, Inc. (STXS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comStereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comStereotaxis Reports 2025 First Quarter Financial ResultsMay 12, 2025 | globenewswire.comStereotaxis Inc (STXS) Q1 2025: Everything You Need to Know Ahead of EarningsMay 10, 2025 | finance.yahoo.comStereotaxis to Showcase GenesisX Robotic System at Heart Rhythm Symposium 2025April 23, 2025 | nasdaq.comStereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025April 22, 2025 | globenewswire.comStereotaxis to feature first-ever live demo of GenesisX Robotic SystemApril 21, 2025 | markets.businessinsider.comStereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025April 21, 2025 | globenewswire.comStereotaxis management to meet virtually with Lake StreetApril 1, 2025 | markets.businessinsider.com3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025March 26, 2025 | zacks.comNvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic SurgeryMarch 24, 2025 | msn.comStereotaxis gains support from NVIDIA for AI roboticsMarch 21, 2025 | uk.investing.comStereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?March 21, 2025 | zacks.comStereotaxis says Nvidia highlighted technology at NVIDIA GTCMarch 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTXS, BVS, RXST, and SIBN Company DescriptionsBioventus NYSE:BVS$6.55 +0.12 (+1.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.56 +0.00 (+0.08%) As of 06/20/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.RxSight NASDAQ:RXST$13.61 -0.26 (-1.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.72 +0.11 (+0.77%) As of 06/20/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.SiBone NASDAQ:SIBN$16.39 -0.29 (-1.74%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$16.39 0.00 (-0.03%) As of 06/20/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Stereotaxis NYSEAMERICAN:STXS$2.04 -0.22 (-9.73%) Closing price 06/20/2025 04:10 PM EasternExtended Trading$2.12 +0.08 (+3.92%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
